191 related articles for article (PubMed ID: 20555320)
1. Renal CD14 expression correlates with the progression of cystic kidney disease.
Zhou J; Ouyang X; Cui X; Schoeb TR; Smythies LE; Johnson MR; Guay-Woodford LM; Chapman AB; Mrug M
Kidney Int; 2010 Sep; 78(6):550-60. PubMed ID: 20555320
[TBL] [Abstract][Full Text] [Related]
2. Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats.
Cowley BD; Ricardo SD; Nagao S; Diamond JR
Kidney Int; 2001 Dec; 60(6):2087-96. PubMed ID: 11737583
[TBL] [Abstract][Full Text] [Related]
3. Spectrum of glomerulocystic kidneys: a case report and review of the literature.
Dedeoglu IO; Fisher JE; Springate JE; Waz WR; Stapleton FB; Feld LG
Pediatr Pathol Lab Med; 1996; 16(6):941-9. PubMed ID: 9025892
[TBL] [Abstract][Full Text] [Related]
4. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
Meijer E; Boertien WE; Nauta FL; Bakker SJ; van Oeveren W; Rook M; van der Jagt EJ; van Goor H; Peters DJ; Navis G; de Jong PE; Gansevoort RT
Am J Kidney Dis; 2010 Nov; 56(5):883-95. PubMed ID: 20888104
[TBL] [Abstract][Full Text] [Related]
5. Clinical and laboratory markers of autosomal dominant polycystic kidney disease (ADPKD) progression: an overview.
Corradi V; Gastaldon F; Virzì GM; Caprara C; Martino F; Ronco C
Minerva Med; 2015 Feb; 106(1):53-64. PubMed ID: 25300895
[TBL] [Abstract][Full Text] [Related]
6. CD14 : a candidate biomarker for the prognosis of polycystic kidney disease.
Vanden Heuvel GB
Kidney Int; 2010 Sep; 78(6):537-8. PubMed ID: 20805816
[TBL] [Abstract][Full Text] [Related]
7. Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy.
Alam A; Dahl NK; Lipschutz JH; Rossetti S; Smith P; Sapir D; Weinstein J; McFarlane P; Bichet DG
Am J Kidney Dis; 2015 Oct; 66(4):564-76. PubMed ID: 25960302
[TBL] [Abstract][Full Text] [Related]
8. Acceleration of polycystic kidney disease progression in cpk mice carrying a deletion in the homeodomain protein Cux1.
Alcalay NI; Sharma M; Vassmer D; Chapman B; Paul B; Zhou J; Brantley JG; Wallace DP; Maser RL; Vanden Heuvel GB
Am J Physiol Renal Physiol; 2008 Dec; 295(6):F1725-34. PubMed ID: 18829740
[TBL] [Abstract][Full Text] [Related]
9. Kidney and cystic volume imaging for disease presentation and progression in the cat autosomal dominant polycystic kidney disease large animal model.
Yu Y; Shumway KL; Matheson JS; Edwards ME; Kline TL; Lyons LA
BMC Nephrol; 2019 Jul; 20(1):259. PubMed ID: 31299928
[TBL] [Abstract][Full Text] [Related]
10. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
[TBL] [Abstract][Full Text] [Related]
11. Hypomagnesaemia is absent in children with autosomal dominant polycystic kidney disease.
Seeman T; Fořtová M; Sopko B; Průša R; Pohl M; John U
Ann Clin Biochem; 2019 Jan; 56(1):90-94. PubMed ID: 29874928
[TBL] [Abstract][Full Text] [Related]
12. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M
BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419
[TBL] [Abstract][Full Text] [Related]
13. Clinical Scenarios in Chronic Kidney Disease: Cystic Renal Diseases.
Meola M; Samoni S; Petrucci I
Contrib Nephrol; 2016; 188():120-30. PubMed ID: 27169740
[TBL] [Abstract][Full Text] [Related]
14. Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models.
Chang MY; Parker E; Ibrahim S; Shortland JR; Nahas ME; Haylor JL; Ong AC
Nephrol Dial Transplant; 2006 Aug; 21(8):2078-84. PubMed ID: 16720597
[TBL] [Abstract][Full Text] [Related]
15. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
Kim K; Trott JF; Gao G; Chapman A; Weiss RH
BMC Nephrol; 2019 Feb; 20(1):66. PubMed ID: 30803434
[TBL] [Abstract][Full Text] [Related]
16. Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2-Dependent Mechanism in Polycystic Kidney Disease.
Dwivedi N; Tao S; Jamadar A; Sinha S; Howard C; Wallace DP; Fields TA; Leask A; Calvet JP; Rao R
J Am Soc Nephrol; 2020 Aug; 31(8):1697-1710. PubMed ID: 32554753
[TBL] [Abstract][Full Text] [Related]
17. Expression and cellular localisation of renal endothelin-1 and endothelin receptor subtypes in autosomal-dominant polycystic kidney disease.
Ong AC; Newby LJ; Dashwood MR
Nephron Exp Nephrol; 2003; 93(2):e80. PubMed ID: 12629276
[TBL] [Abstract][Full Text] [Related]
18. The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression.
Neijenhuis MK; Kievit W; Perrone RD; Sloan JA; Erwin P; Murad MH; Gevers TJG; Hogan MC; Drenth JPH
BMC Nephrol; 2017 May; 18(1):169. PubMed ID: 28545401
[TBL] [Abstract][Full Text] [Related]
19. TGF-beta mediated epithelial-mesenchymal transition in autosomal dominant polycystic kidney disease.
Chea SW; Lee KB
Yonsei Med J; 2009 Feb; 50(1):105-11. PubMed ID: 19259356
[TBL] [Abstract][Full Text] [Related]
20. Modification of disease progression in rats with inherited polycystic kidney disease.
Cowley BD; Grantham JJ; Muessel MJ; Kraybill AL; Gattone VH
Am J Kidney Dis; 1996 Jun; 27(6):865-79. PubMed ID: 8651252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
